An important finding of this study that is potentially relevant to practice is that inhibiting cytosolic aspartate biosynthesis by targeting GOT1 is likely an approach to sensitize glycolysis-competent CRC to OXPHOS inhibitors. Here, GOT1 is linked to colorectal carcinoma.